According to a data presented at a medical meeting on Saturday, Pfizer Inc. manufactured drug Xalkori, which has been quite effective in treating lung cancer patients with specific tumors, will now be shrinking the tumors and even few rare forms of the disease too. Xalkori is a prescription medicine and treats non-small cell lung cancer that has spread to all parts of body due to a defect in a gene known as ALK fusion gene. Chemically known as crizotinib, diagnostically it could test the mutations in the gene. About one to two percent of these patients are believed to be ROS1 positive, a situation where two separate genes get fused and combines. This fusion of otherwise split genes, can cause wide range of cancers in humans and NSCLC is one such type.
The study was conducted on fifty patients suffering from (NSCLC). Their cancer was a result of rearrangement of the ROS1 gene. In 72% of the people, the drug could condense the growth of the tumor significantly. And in the nine percent the tumor was actually halted from growth.